Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cachexia Clear all
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

NCT03207724
View directory record Official record
Conditions
Pancreatic Cancer, Cachexia, Weight Loss
Interventions
Xilonix plus Onivyde and 5FU
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 3 Interventional

A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

NCT00002067
View directory record Official record
Conditions
Anorexia, Cachexia, HIV Infections
Interventions
Megestrol acetate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 4, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

NCT00513357
View directory record Official record
Conditions
Gastrointestinal Cancer, Lung Cancer
Interventions
Melatonin, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Wasting Disease
Interventions
Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 4, 2026, 2:37 AM EDT
Recruiting No phase listed Observational

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

NCT05376592
View directory record Official record
Conditions
Pancreas Adenocarcinoma, Cachexia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT01355484
View directory record Official record
Conditions
Muscle Wasting, Non Small Cell Lung Cancer
Interventions
GTx-024, placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Aventura, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

NCT00000925
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Optimune oral nutritional supplement
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 4, 2026, 2:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology

NCT03012139
View directory record Official record
Conditions
Metastatic Cancer, Cachexia; Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

NCT00815685
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Eicosapentaenoic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 4, 2026, 2:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mitochondrial Respiratory Function in Mammalian Skeletal Muscle

NCT02650570
View directory record Official record
Conditions
Cancer, Cachexia
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

NCT00000854
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Nandrolone decanoate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Results available

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions
PF-06946860, Placebo for PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss

NCT00094562
View directory record Official record
Conditions
Cancer, Cancer Cachexia, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure, Rheumatoid Arthritis
Interventions
Fish oil supplement
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Sep 4, 2026, 2:37 AM EDT
Recruiting No phase listed Observational

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

NCT06073431
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Medical Device Usage and Evaluation, Physical Performance Testing, Positron Emission Tomography, Survey Administration
Procedure · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
225
States / cities
Fort Smith, Arkansas • Aurora, Colorado • Boulder, Colorado + 160 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

NCT00000737
View directory record Official record
Conditions
Cachexia, HIV Infections, HIV Wasting Syndrome
Interventions
Dronabinol, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Denver, Colorado • Chicago, Illinois • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2008 · Synced Sep 4, 2026, 2:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

NCT00994669
View directory record Official record
Conditions
Cachexia
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

NCT01355497
View directory record Official record
Conditions
Muscle Wasting, Non-Small Cell Lung Cancer
Interventions
GTx-024, placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 4, 2026, 2:37 AM EDT
Withdrawn No phase listed Observational

Observational Study of Insulin Resistance and Muscle Wasting After Burn Injury

NCT02029261
View directory record Official record
Conditions
Burn
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 4, 2026, 2:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

NCT07429240
View directory record Official record
Conditions
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Interventions
PBGENE-DMD (IV)
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
2 Years to 7 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 4, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

NCT00002157
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Warren Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 4, 2026, 2:37 AM EDT
Completed No phase listed Observational

A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements

NCT00001077
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Multivitamin and mineral supplements, Peptamen, NuBasics
Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 4, 2026, 2:37 AM EDT
Terminated Phase 2 Interventional Results available

Anamorelin Study for Advanced Pancreatic Cancer

NCT04844970
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Anamorelin Hydrochloride, Placebo
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 4, 2026, 2:37 AM EDT